ImmunoGen, Inc. Announces Conference Call to Discuss Its First Quarter Fiscal Year 2008 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 25, 2007--ImmunoGen, Inc. (Nasdaq:IMGN) will host a conference call at 4:30 pm ET on Thursday, November 1, 2007 to discuss the Company's financial results for the three-month period ended September 30, 2007 - the first quarter of ImmunoGen's 2008 fiscal year. Management also will provide an update on the Company.
To access the live call by phone, dial 913-981-4900. No passcode is required. The call also may be heard through the Investor Relations section on the Company's website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through November 8, 2007.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing - huN901-DM1 and huC242-DM4. Three TAP compounds are in clinical testing through ImmunoGen's collaborations with other companies - AVE9633 and SAR3419, in development by sanofi-aventis, and trastuzumab-DM1 (T-DM1), in development by Genentech. Additionally, the naked antibody compound, AVE1642, is in development through the Company's collaboration with sanofi-aventis. Multiple compounds are in research/preclinical development through the ImmunoGen's collaborations and internal programs.
CONTACT:
ImmunoGen, Inc.
Carol Hausner, 617-995-2500
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com
